Skip to content
DraconiticResearch
Search Sources API
181,713 studies31 sourcesUpdated 9 min ago
Peer-reviewedCC BY-NC-NDMolecular and clinical oncology

PHLPP2 expression and its clinical significance in multiple myeloma.

  • Jing Li1,2
  • Yanxia Jiang3
  • Guoan Chen2
  1. 1Department of Blood Transfusion, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510000, P.R. China.
  2. 2Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China.
  3. 3Department of Endocrinology and Metabolism, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China.
Read full textPDFDOICite

Abstract

PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) is downregulated in most malignant tumors, and can promote tumor development and progression. However, the clinical significance of PHLPP2 in multiple myeloma (MM) has remained elusive. The aim of the present study was to assess the expression and prognostic significance of PHLPP2 in patients with MM. Reverse transcription-quantitative PCR and immunohistochemistry were performed to detect the expression of PHLPP2 in samples from patients with MM and healthy volunteers. The results demonstrated that the mRNA expression levels of PHLPP2 were decreased in plasma and bone marrow samples from 16 patients with MM compared with those from 16 healthy controls. Furthermore, the protein expression of PHLPP2 was significantly different between the patients with MM and controls (P<0.05). This finding was related to the Revised International Staging System (R-ISS) (P=0.028), regardless of sex or age. Furthermore, the expression of PHLPP2 was decreased in the newly diagnosed group compared with that in the effective-treatment group (P=0.0077). In conclusion, the current study demonstrated that PHLPP2 expression is low in MM and decreases with advancing R-ISS stage, indicating that PHLPP2 may inhibit the progression of MM and low expression may be a marker of poor clinical prognosis.

Related

  1. Hemophagocytic Lymphohistiocytosis as a Clinical Harbinger of Rapid Disease Progression in Multiple Myeloma During Daratumumab-Based Therapy
    Hisaharu Shikata, Masahiko Kaneko, Shoichi Matsukage
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  2. Advancing T Cell Engagers in Multiple Myeloma: Structural Design and Clinical Optimization to Address Current Limitations.
    Linyu Cai, Yuxuan Ding, Jinhua Wang +6
    Drug design, development and therapyPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  3. Expression and clinical significance of miR-34a-5p in lumbar disc herniation.
    Boyu Song, Rui Dong, Tingting Liu +3
    Journal of orthopaedic surgery and researchPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCDOAJ
  4. The landscape and plasticity of transposable element expression in an adult stem cell of high physiological and clinical significance.
    Xingyu Fu, Qiangwei Cai, Jingjing Zhao +16
    Cell death discoveryPeer-reviewedCC BYFull textHuman geneticsEurope PMCPMC
  5. Expression and clinical significance of WBC, hs-CRP, and ROMA index, and tumor markers in endometriosis
    Jiao Li, Kangying Wang
    BMC Women's HealthPeer-reviewedCC BY-NC-ND 4.0Full textObstetrics, gynaecology & paediatricsPMC

Cite

BibTeXRIS
BibTeX
@article{li2026phlpp2,
  title = {{PHLPP2 expression and its clinical significance in multiple myeloma.}},
  author = {Jing Li and Yanxia Jiang and Guoan Chen},
  journal = {Molecular and clinical oncology},
  year = {2026},
  month = sep,
  doi = {10.3892/mco.2026.2977},
  url = {https://europepmc.org/article/MED/42923862},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - PHLPP2 expression and its clinical significance in multiple myeloma.
AU  - Jing Li
AU  - Yanxia Jiang
AU  - Guoan Chen
PY  - 2026
DA  - 2026/09/30
JO  - Molecular and clinical oncology
DO  - 10.3892/mco.2026.2977
UR  - https://europepmc.org/article/MED/42923862
AB  - PH domain leucine-rich repeat protein phosphatase 2 (PHLPP2) is downregulated in most malignant tumors, and can promote tumor development and progression. However, the clinical significance of PHLPP2 in multiple myeloma (MM) has remained elusive. The aim of the present study was to assess the expression and prognostic significance of PHLPP2 in patients with MM. Reverse transcription-quantitative PCR and immunohistochemistry were performed to detect the expression of PHLPP2 in samples from patients with MM and healthy volunteers. The results demonstrated that the mRNA expression levels of PHLPP2 were decreased in plasma and bone marrow samples from 16 patients with MM compared with those from 16 healthy controls. Furthermore, the protein expression of PHLPP2 was significantly different between the patients with MM and controls (P<0.05). This finding was related to the Revised International Staging System (R-ISS) (P=0.028), regardless of sex or age. Furthermore, the expression of PHLPP2 was decreased in the newly diagnosed group compared with that in the effective-treatment group (P=0.0077). In conclusion, the current study demonstrated that PHLPP2 expression is low in MM and decreases with advancing R-ISS stage, indicating that PHLPP2 may inhibit the progression of MM and low expression may be a marker of poor clinical prognosis.
SN  - 2049-9450
SN  - 2049-9469
ER  -